Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Cl

Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical...

Related Keywords

New York , United States , Memorial Sloan Kettering Cancer Center , Cambridge , Cambridgeshire , United Kingdom , Spain , Barcelona , Comunidad Autonoma De Cataluna , Kristinl Andrews , Alexander Drilon , Anupong Tangpeerachaikul , Prnewswire Nuvalent Inc , Md Memorial Sloan Kettering Cancer Center , Nuvalent Inc , Twitter , Selection Of Third Development , Nasdaq , Preliminary Dose Escalation Data , Preclinical Data , Clinical Stage Candidate , Third Development Candidate , Potential Best In Class , Positive Cancers , Preclinical Characterization , Host Conference Call , Data Presentation , Molecular Targeted , New Drugs , Plenary Session , Poster Session , Molecular Targeted Agents , Nuvalent , Nc , Medical Pharmaceuticals , Health Care Amp Hospitals , Pharmaceuticals , Biotechnology , Clinical Trials Amp Medical Discoveries , Trade Show News , Roadcast Feed Annoucement ,